Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Published:2019-07-27 Issue:11 Volume:8 Page:5173-5182
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Etienne Gabriel¹²³^ORCID,Dulucq Stéphanie⁴,Huguet Françoise³⁵,Schmitt Anna¹,Lascaux Axelle⁶,Hayette Sandrine⁷,Fort Marie‐Pierre¹,Sujobert Pierre⁷,Bijou Fontanet¹,Morisset Stéphane⁸,Tavitian Suzanne⁵,Bidet Audrey⁴,Turcq Beatrice²,Robbesyn Fanny⁴,Chollet Claudine⁴,Belloc Francis²,Durrieu Françoise¹,Mahon François‐Xavier¹²³⁴,Nicolini Franck E.³⁸⁹¹⁰

Affiliation:

1. Département d'Hématologie Institut Bergonié Bordeaux France

2. Laboratory of Mammary and Leukaemic Oncogenesis INSERM U1218, Université de Bordeaux Bordeaux France

3. Groupe Fi‐LMC, Hôpital Haut‐Lévêque Pessac France

4. Laboratoire d'Hématologie Hôpital Haut Lévêque CHU de Bordeaux Pessac France

5. Service d'Hématologie Institut Universitaire du Cancer Toulouse‐Oncopole, Centre Hospitalier Universitaire Toulouse France

6. Service des maladies du sang Hôpital Haut Lévêque CHU de Bordeaux Pessac France

7. Laboratoire d'Hématologie Centre Hospitalier Lyon Sud Pierre Bénite France

8. Hematology Department Centre Léon Bérard Lyon France

9. Service d'Hématologie et INSERM U 1052, CRCL, Centre Léon Bérard Lyon France

10. INSERM U1052, CRCL, Centre Léon Bérard Lyon France

Publisher